Predicting responses to arthritis treatments

Predicting responses to arthritis treatments

BioPharma Predicting responses to arthritis treatments using machine learning Biological therapies can slow down the progression of rheumatoid arthritis. There are multiple drugs available – which one works best depends upon the patient’s genetics.  There...
Reversing tumour resistance to kinase inhibitors

Reversing tumour resistance to kinase inhibitors

BioPharma Reversing tumour resistance to kinase inhibitors Drug resistance is behind most relapses in cancer patients. This is partly why anti-cancer drugs targeting oncogenic kinase signalling have failed to live up to expectations. Kinase inhibitors are only...
Restorative treatments for osteoarthritis

Restorative treatments for osteoarthritis

BioPharma Restorative treatments for osteoarthritis There’s no cure for osteoarthritis. Current treatment for this debilitating joint disease involves managing symptoms and replacing joints. Professor Francesco Dell’Accio and his team have invented three novel and...
Using Resolvins to assess the risk of Cardiovascular Diseases

Using Resolvins to assess the risk of Cardiovascular Diseases

BioPharma Using n-3 DPA-derived Resolvins to assess the risk of Cardiovascular Diseases A novel therapeutic strategy, using n-3 DPA-derived resolvins to treat or prevent cardiovascular disease. Circadian rhythms play a key role in regulating various physiological...
Restoring Erythropoiesis in Myelodysplastic Syndrome

Restoring Erythropoiesis in Myelodysplastic Syndrome

BioPharma Restoring Erythropoiesis in Myelodysplastic Syndrome Researchers at QMUL and Université de Bretagne-Occidentale have developed a method of restoring erythropoiesis in a patient suffering from a SF3B1 mutant myelodysplastic syndrome, involving the...